États-Unis - anglais - NLM (National Library of Medicine)

teva parenteral medicines, inc. - enoxaparin sodium (unii: 8nz41mik1o) (enoxaparin - unii:e47c0nf7lv) - enoxaparin sodium 30 mg in 0.3 ml - enoxaparin sodium injection is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): - in patients undergoing abdominal surgery who are at risk for thromboembolic complications [see clinical studies (14.1) ] - in patients undergoing hip replacement surgery, during and following hospitalization - in patients undergoing knee replacement surgery - in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness enoxaparin sodium injection is indicated for: - the inpatient treatment of acute deep vein thrombosis with or without pulmonary embolism , when administered in conjunction with warfarin sodium - the outpatient treatment of acute deep vein thrombosis without pulmonary embolism when administered in conjunction with warfarin sodium enoxaparin sodium injection is indicated for the prophylaxis of ischemic complications of unstable angina and non-q-wave myocardial infarction, when concurrently admin

États-Unis - anglais - NLM (National Library of Medicine)

virtus pharmaceuticals, llc - tranexamic acid (unii: 6t84r30kc1) (tranexamic acid - unii:6t84r30kc1) - tranexamic acid 100 mg in 1 ml - tranexamic acid is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. tranexamic acid injection is contraindicated: risk summary available data from published studies, case series and case reports with tranexamic acid use in pregnant women in the second and third trimester and at the time of delivery have not clarified whether there is a drug-associated risk of miscarriage or adverse maternal or fetal outcomes. there are 2 (0.02%) infant cases with structural abnormalities that resulted in death when tranexamic acid was used during conception or the first trimester of pregnancy; however, due to other confounding factors the risk of major birth defects with use of tranexamic acid during pregnancy is not clear. tranexamic acid is known to pass the placenta and appears in cord blood at concentrations approximately equal to maternal concentration (see data ). reproduction studies

États-Unis - anglais - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - acyclovir (unii: x4hes1o11f) (acyclovir - unii:x4hes1o11f) - acyclovir 400 mg - herpes zoster infections: acyclovir tablets, usp are indicated for the acute treatment of herpes zoster (shingles). genital herpes: acyclovir tablets, usp are indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. chickenpox: acyclovir tablets, usp are indicated for the treatment of chickenpox (varicella). acyclovir tablets are contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir.

États-Unis - anglais - NLM (National Library of Medicine)

zydus lifesciences limited - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th), losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - hydrochlorothiazide 12.5 mg - losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (cv) events, primarily strokes and myocardial infarction. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, f

États-Unis - anglais - NLM (National Library of Medicine)

trinity pharmaceuticals, llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 100 mg in 1 g - indications: sulfacetamide sodium and sulfur cleanser is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. contraindications: sulfacetamide sodium and sulfur cleanser is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. sulfacetamide sodium and sulfur cleanser is not to be used by patients with kidney disease. pediatric use - safety and effectiveness in children under the age of 12 have not been established.

États-Unis - anglais - NLM (National Library of Medicine)

geigy pharmaceuticals - imipramine hydrochloride (unii: bke5q1j60u) (imipramine - unii:ogg85sx4e4) - injection, solution - 25 mg in 2 ml - depression : for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute tofranil in patients receiving a monoamine oxidase inhibitor, as long an interval should elapse as the clinical situation will allow, with a minimum of 14 days. initial dosage should be low and increases should be gradual and cautiously prescribed. the drug is contraindicated during the acute recovery period after a myocardial infarction. patients with a known hypersensitivity to this compound should not be given the drug. the possibility of cross-sensitivity to other dibenzazepine compounds should be k

États-Unis - anglais - NLM (National Library of Medicine)

karalex pharma, llc, woodcliff lake, nj 07677 - malathion (unii: u5n7su872w) (malathion - unii:u5n7su872w) - malathion 5 mg in 1 ml - malathion lotion is indicated for patients infected with pediculus humanus capitis (head lice and their ova) of the scalp hair. malathion lotion is contraindicated for neonates and infants because their scalps are more permeable and may have increased absorption of malathion. malathion lotion should also not be used on individuals known to be sensitive to malathion or any of the ingredients in the vehicle. the safety and effectiveness of malathion lotion in children less than 6 years of age has not been established via well-controlled trials.

États-Unis - anglais - NLM (National Library of Medicine)

belcher pharmaceuticals, llc - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium cation 4.1 meq in 1 g - sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. sodium polystyrene sulfonate for suspension is contraindicated in the following conditions: patients with hypokalemia, patients with a history of hypersensitivity to polystyrene sulfonate resins, obstructive bowel disease, neonates with reduced gut motility (postoperatively or drug induced) and oral administration in neonates (see precautions).

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

colorama pharmaceuticals ltd - diclofenac diethylammonium - cutaneous gel - 23.2mg/1gram

États-Unis - anglais - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 4 g in 50 ml - magnesium sulfate in water for injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. when used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. however, other effective drugs are available for this purpose. intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery.